Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Open-Label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion.

Rodriguez CI, Levinson A, Zwerling J, Vermes D, Simpson HB.

J Clin Psychiatry. 2016 May;77(5):688-9. doi: 10.4088/JCP.15l10318. No abstract available.

2.

COMBINED MIRTAZAPINE AND SSRI TREATMENT OF PTSD: A PLACEBO-CONTROLLED TRIAL.

Schneier FR, Campeas R, Carcamo J, Glass A, Lewis-Fernandez R, Neria Y, Sanchez-Lacay A, Vermes D, Wall MM.

Depress Anxiety. 2015 Aug;32(8):570-9. doi: 10.1002/da.22384. Epub 2015 Jun 26.

3.

In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept.

Rodriguez CI, Kegeles LS, Levinson A, Ogden RT, Mao X, Milak MS, Vermes D, Xie S, Hunter L, Flood P, Moore H, Shungu DC, Simpson HB.

Psychiatry Res. 2015 Aug 30;233(2):141-7. doi: 10.1016/j.pscychresns.2015.06.001. Epub 2015 Jun 6.

4.

Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.

Foa EB, Simpson HB, Rosenfield D, Liebowitz MR, Cahill SP, Huppert JD, Bender J Jr, McLean CP, Maher MJ, Campeas R, Hahn CG, Imms P, Pinto A, Powers MB, Rodriguez CI, Van Meter PE, Vermes D, Williams MT.

J Clin Psychiatry. 2015 Apr;76(4):440-6. doi: 10.4088/JCP.14m09044.

5.
6.

Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J Jr, Marcus SM, Williams MT, Weaver J, Vermes D, Van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P, Hahn CG, Campeas R.

JAMA Psychiatry. 2013 Nov;70(11):1190-9. doi: 10.1001/jamapsychiatry.2013.1932.

7.

Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.

Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, Flood P, Simpson HB.

Neuropsychopharmacology. 2013 Nov;38(12):2475-83. doi: 10.1038/npp.2013.150. Epub 2013 Jun 19.

8.

Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder.

Foa EB, Simpson HB, Liebowitz MR, Powers MB, Rosenfield D, Cahill SP, Campeas R, Franklin M, Hahn CG, Hembree EA, Huppert JD, Schmidt AB, Vermes D, Williams MT.

J Clin Psychiatry. 2013 May;74(5):464-9. doi: 10.4088/JCP.12m08017.

9.

A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder.

Blanco C, Heimberg RG, Schneier FR, Fresco DM, Chen H, Turk CL, Vermes D, Erwin BA, Schmidt AB, Juster HR, Campeas R, Liebowitz MR.

Arch Gen Psychiatry. 2010 Mar;67(3):286-95. doi: 10.1001/archgenpsychiatry.2010.11.

10.

A double-masked, placebo-controlled study of fluoxetine for hypochondriasis.

Fallon BA, Petkova E, Skritskaya N, Sanchez-Lacay A, Schneier F, Vermes D, Cheng J, Liebowitz MR.

J Clin Psychopharmacol. 2008 Dec;28(6):638-45. doi: 10.1097/JCP.0b013e31818d21cf.

PMID:
19011432
11.

A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.

Simpson HB, Foa EB, Liebowitz MR, Ledley DR, Huppert JD, Cahill S, Vermes D, Schmidt AB, Hembree E, Franklin M, Campeas R, Hahn CG, Petkova E.

Am J Psychiatry. 2008 May;165(5):621-30. doi: 10.1176/appi.ajp.2007.07091440. Epub 2008 Mar 3.

12.

A randomized trial of interpersonal therapy versus supportive therapy for social anxiety disorder.

Lipsitz JD, Gur M, Vermes D, Petkova E, Cheng J, Miller N, Laino J, Liebowitz MR, Fyer AJ.

Depress Anxiety. 2008;25(6):542-53.

PMID:
17941096
13.

A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults.

Marshall RD, Lewis-Fernandez R, Blanco C, Simpson HB, Lin SH, Vermes D, Garcia W, Schneier F, Neria Y, Sanchez-Lacay A, Liebowitz MR.

Depress Anxiety. 2007;24(2):77-84.

PMID:
16892419
14.

An open pilot study of interpersonal psychotherapy for panic disorder (IPT-PD).

Lipsitz JD, Gur M, Miller NL, Forand N, Vermes D, Fyer AJ.

J Nerv Ment Dis. 2006 Jun;194(6):440-5.

PMID:
16772862
15.

An open trial of fluvoxamine for hypochondriasis.

Fallon BA, Qureshi AI, Schneier FR, Sanchez-Lacay A, Vermes D, Feinstein R, Connelly J, Liebowitz MR.

Psychosomatics. 2003 Jul-Aug;44(4):298-303.

PMID:
12832595
16.

Childhood trauma and dissociative symptoms in panic disorder.

Marshall RD, Schneier FR, Lin SH, Simpson HB, Vermes D, Liebowitz M.

Am J Psychiatry. 2000 Mar;157(3):451-3.

PMID:
10698824
17.

Low dose selegiline (L-Deprenyl) in social phobia.

Simpson HB, Schneier FR, Marshall RD, Campeas RB, Vermes D, Silvestre J, Davies S, Liebowitz MR.

Depress Anxiety. 1998;7(3):126-9. No abstract available.

PMID:
9656093
18.

The pharmacotherapy of hypochondriasis.

Fallon BA, Schneier FR, Marshall R, Campeas R, Vermes D, Goetz D, Liebowitz MR.

Psychopharmacol Bull. 1996;32(4):607-11. Review.

PMID:
8993081
19.

A computerized intervention to improve timing of outpatient follow-up: a multicenter randomized trial in patients treated with warfarin. National Consortium of Anticoagulation Clinics.

Fihn SD, McDonell MB, Vermes D, Henikoff JG, Martin DC, Callahan CM, Kent DL, White RH.

J Gen Intern Med. 1994 Mar;9(3):131-9.

PMID:
8195911
20.

Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group.

Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH.

Ann Intern Med. 1993 Apr 1;118(7):511-20.

PMID:
8280198

Supplemental Content

Loading ...
Support Center